Pharma IP teams are used to thinking in timelines: filing dates, priority windows, prosecution milestones, andeventuallypatent expiry. But in Russia, the clock is getting more complicated, and the consequences are immediate.
Russias approach to patent …

Litigation-Aware Prosecution: Turn Your Drug Patent Portfolio Into a Competitive Assertion Asset
Most pharma teams still treat patent strategy like a filing exercise: draft, file, wait, and hope the claims hold up later. But in todays environmentwhere …

Hospitals are sitting on a quiet competitive advantageand many are ignoring it.
In the pharmaceutical market, timing is everything. Patent cliffs dont just change drug prices; they reshape formularies, procurement leverage, and patient access. Yet a gr…

Generic launches dont just happen. They arrive on a calendar built from legal filings, patent estates, and regulatory timing. The winners arent the teams with the best spreadsheetstheyre the teams with the best patent intelligence.
Most pharma and biot…

Pharmas hidden talent isnt in the labits in the Orange Book.
If youve ever wondered where the next wave of drug innovation is coming from, you dont have to guess. The FDAs Orange Bookoften treated like a compliance artifactquietly functions as a live…

Biotech investors love pipeline value, but most portfolio rankings still miss the point.
A company can have a long list of programs and still be quietly destroying shareholder valuebecause the programs arent being prioritized by how much theyre likely …

Biopharma is entering a new kind of patent cliffnot just for revenue, but for talent.
When blockbuster exclusivities expire, the industry doesnt just lose market share. It loses momentum. Teams get reorganized. Budgets tighten. Hiring freezes appear. A…

Overstocking branded drugs isnt just a balance-sheet problemits a patent-timing problem.
For wholesalers, the margin story is familiar: buy right, ship fast, manage service levels. But the real risk often hides in plain sightinside the patent calenda…

Big Pharma doesnt just feel a patent cliffit hires like it does.
When blockbuster exclusivity ends, the industrys first instinct isnt always a press release. Its a staffing signal: new roles posted, teams reorganized, and specialized talent pulled into…

Biosimilar sourcing isnt a procurement problemits a patent strategy problem.
If youre planning a switch from an originator to a biosimilar, the hardest part usually isnt identifying candidates. Its timing the switch so you capture volume and margin bef…